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Summary
Objectives: To evaluate the viral, immune and clinical impact of a structured treatment
interruption (STI) program of highly active antiretroviral therapy (HAART) in three cycles of 4
weeks off/12 weeks on therapy in a cohort of children with HIV infection under chronic viral
control.
Methods: Using a single-group time series experimentation design and following informed
consent, the HAART of children with HIV and a chronically undetectable viral load (VL) was
discontinued for 4 weeks and then restarted and continued for 12 weeks for a total of three
cycles. The VL, CD4+/CD8+ lymphocytes, and clinical status were evaluated at the end of each STI
and at 6 and 12 weeks after HAART was resumed.
* Corresponding author. Tel.: +52 81 8371 4100x41315; fax: +52 81 8371 4100x41315.
** Corresponding author.
E-mail address: palsaugc@gmail.com (G.C. Palacios).
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Results: Four childrenwith amedian age of 10.3 years (range 6.5—11.2 years) were included in the
study. Their clinical immune categories were: A1 (n = 2), A2 (n = 1), and B3 (n = 1). Treatment of all
four patients waswith zidovudine (AZT) + lamivudine (3TC) + ritonavir (RTV). At the end of the first
STI, VL was a median 214000 copies/ml (range 27400—616000), corresponding to 5.3 log10 (range
4.4—5.8). At the end of the second STI, VL was a median 72400 copies/ml (range 17800—126000) or
4.7 log10 (range4.2—5.1),which corresponds toa rebound0.6 log10 lower than thefirst.At theendof
the third STI, VLwas amedian 28200 copies/ml (range 5370—140000) or 4.45 log10 (range 3.7—5.1),
a rebound 0.85 log10 lower than the first. All rebounds were followed by a decrease in the VL to
undetectable levels during the treatment periods. CD8+ T lymphocyte counts increased during viral
rebounds and an initial decrease in CD4+ T lymphocyte counts was followed by a tendency to
increase evenexceeding CD8+ Tcell counts.Only one event of transitory severe immunosuppression
occurred. There were no symptoms related to the HIV infection.
Conclusions: The STI of HAART in cycles of 4 weeks off/12 weeks on therapy in children with
chronically undetectable VL can cause progressively lower viral rebounds followed by a decrease to
undetectable levels, with a low risk of severe immunosuppression and without the occurrence of
symptoms related to HIV.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The use of highly active antiretroviral therapy (HAART) has
increased the survival of HIV-infected children and has
improved their quality of life.1,2 However, due to the fact that
it is a lifetime treatment, it faces limitations related to costs,
toxicity, and treatment adherence, which accumulate as time
goes by.1,3—7 Patients who interrupt HAART without medical
indications experience a rapid viral load (VL) rebound followed
by depletion of CD4+ lymphocytes.8—11 In contrast, during
structured treatment interruptions (STI) of HAART, controlled
increases in viral replication could promote the development
of a specific immune response against HIV, which in turn could
cause a delay in the VL rebound,with a greater delaywith each
interruption.9,12 This strategy could contribute to reducing the
chronic toxicity of antiretroviral drugs, decreasing treatment
costs and improving patient quality of life. Information avail-
able on STI of HAART in pediatric patients is scarce and that
which refers to adult patients remains controversial.12—17 The
objective of this study was to evaluate the viral, immune, and
clinical impact of an STI program of HAART in three cycles of 4
weeks off/12 weeks on therapy in a cohort of childrenwith HIV
infection under chronic viral control.
Materials and methods
Patient sample
The sample included HIV-1-infected children with VL under
the detection limit (<400 copies/ml) by HAART, without
immunosuppression (according to the 1994 Centers for Dis-
ease Control and Prevention (CDC) classification18), and who
had been asymptomatic at least during the previous 12
months. Exclusion criteria were: (1) failure to complete
30% or more of the evaluations during the follow-up (they
had to complete at least 14 of the 20 scheduled measure-
ments) and (2) voluntary withdrawal from the study due to a
decision by the parents, the person legally responsible for the
patient’s welfare, or the patient themselves, as applicable.
Written informed consent was obtained from the parents or
the person legally responsible for the patient. The study wasapproved by the institutional research and ethics review
board of the Hospital de Especialidades No. 25.
Experimental design
A case series of four children was evaluated through a single-
group time series design with multiple treatment and with-
drawal periods. The HAARTof each child was interrupted for 4
weeks, followed by 12 weeks on HAART, until three inter-
ruption/restart cycles (4 weeks off/12 weeks on therapy)
were completed. The drugs used for each patient remained
identical during the study. Response was evaluated by mea-
suring VL, CD4+ and CD8+ lymphocyte counts, and the clinical
status of each patient at baseline, at the end of each inter-
ruption period, and at 6 and 12 weeks after restarting HAART.
VL was measured by RT-PCR using the Cobas Amplicor HIV-1
Monitor test, version 1.5 (Roche Diagnostics, Branchburg, NJ,
USA), which has a detection limit of 400 copies/ml. T lym-
phocyte subpopulations were measured by standard flow
cytometric methods, classifying the degree of immunodefi-
ciency by age according to the 1994 CDC classification.18
Treatment safety and adherence
Toxicity related to HAART was evaluated at each follow-up
appointment, both clinically and by means of complete blood
counts and routine biochemical values (including serum liver
enzymes, amylase, lipase, lipids and cholesterol). Adherence
to HAART was evaluated for each patient during outpatient
appointments by the following means: (1) offering informa-
tion, before entering into the study and during follow-up, to
the parents or the persons legally responsible for the patient,
and to the patient when appropriate, on the importance of
HAARTand of adhering to it as planned, as well as information
on the potential risks of interrupting it without medical
indications; (2) guided questioning of the parents, the per-
sons responsible for administrating treatment, or the
patient, about maintaining treatment as it was established;
(3) asking the parents or guardians to fill out self-adminis-
tration cards specially designed to optimize follow-up and
to avoid involuntary forgetfulness; and (4) counting the
Table 1 Baseline characteristics of four HIV-1-infected children included in a structured treatment interruption program (STI) of
HAART in cycles of 4 weeks off/12 weeks on therapy.
Patient 1 Patient 2 Patient 3 Patient 4
Age (years) 6.5 11.2 7.3 8.4
Sex Female Female Female Male
Previous ART (months) — AZT + ddC (28) — —
IDV + AZT + 3TC (61)
HAART regimena (months) RTV + AZT + 3TC (53) RTV + AZT + 3TC (8) RTV + AZT + 3TC (36) RTV + AZT + 3TC (29)
Viral load <400 copies/ml
(<2.6 log10/ml)
<400 copies/ml
(<2.6 log10/ml)
<400 copies/ml
(<2.6 log10/ml)
<400 copies/ml
(<2.6 log10/ml)
Clinical immune categoryb A2 A1 B3 A1
ART, antiretroviral treatment; HAART, highly active antiretroviral therapy; AZT, zidovudine; ddI, didanosine; IDV, indinavir; 3TC, lamivudine;
RTV, ritonavir.
a At the beginning of the structured treatment interruption program.
b According to the 1994 Centers for Disease Control and Prevention (CDC) classification.18
Figure 1 Viral load as the number of copies of viral RNA/ml
(filled squares) and the log10 of that number (empty circles) of
four HIV-1 infected children in a structured treatment interrup-
tion program (STI) in cycles of 4 weeks off/12 weeks on HAART. Xn
are the 4-week treatment interruption periods. Values corre-
spond to median and quartiles 25 and 75.
e36 G.C. Palacios et al.remaining medication, comparing it to what should have
been consumed by the patient.
Statistical analysis
Median, ranges and quartiles 25 and 75 were used to describe
the main results. The differences in VL and T lymphocyte
counts over time, during HAART interruptions, and during
periods on HAART, were evaluated through a visual graphic
analysis and the Friedman analysis of variance for repeated
measures. Analysis was carried out using SPSS version 15.0
(SPSS Inc., Chicago, IL, USA). A p-value of <0.05 was con-
sidered to be significant.19
Results
General characteristics of the patients
Between April and May 2004, four children were eligible and
included in the study, three females and one male, with a
median age of 10.3 years (range 6.5—11.2 years). All four
patients acquired the HIV infection perinatally. The clinical
immune categories were: A1 (n = 2), A2 (n = 1), and B3
(n = 1). The four patients were receiving the zidovudine
(AZT) + lamivudine (3TC) + ritonavir (RTV) HAART regimen
at the recommended pediatric dosages.1,3 Full-dose RTV as
the only protease inhibitor was still recommended for the
initial HAART regimen in children in Mexico when this study
began.3,5,20 One of the patients had previously received two
regimens, the latter based on indinavir (IDV) + AZT + 3TC.
The IDV was changed to RTV due to drug toxicity (Table 1).
Viral response
All four children had a VL under the detection limit at least
during the 12months before enrollment. At the end of the first
period of 4weeks of HAART interruption, the viral reboundwas
a median 214 000 copies/ml (range 27 400—616 000) or 5.3
log10 (range 4.4—5.8). VL fell under the detection limit at 6
weeks after resuming HAARTand remained that way at the 12-
weekmeasurement. Because this first viral reboundwas higher
than we expected but VL decreased to undetectable levelsafter resuming treatment, we requested authorization to
continue with the next interruption/resumption cycles from
the ethics review board of the Hospital de Especialidades No.
25. Researchers expected VL rebounds to be no more than 4
log10 at the end of each HAART interruption period of 4
weeks.17,21 The ethics review board decided to approve con-
tinuing the trial on the basis of the reduction of VL to unde-
tectable levels after resuming HAART. With the second
interruption,VL increased toamedian72400 copies/ml (range
17 800—126 000) or 4.7 log10 (range 4.2—5.1), which corre-
sponds to a rebound 0.6 log10 lower than the first (p = 0.068).
At the end of the third interruption, the VL rebound was a
median 28 200 copies/ml (range 5370—140 000) or 4.45 log10
(3.7—5.1),a rebound0.85 log10 lower thanthefirst (p = 0.050).
All rebounds were followed by a decrease in the VL to unde-
tectable levels during periods onHAART, except in the case of a
female child who had a VL of 9530 copies/ml (3.98 log10) 12
weeks after the third restart, which coincided with an upper
respiratory tract infection; this infectionwasprobably viral but
had an undetermined etiology. Six weeks later, the VL became
undetectable in this patient (Table 2 and Figure 1).
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Important increases in the CD8+ T lymphocyte counts were
observed during the treatment interruption periods, which
coincided with the virological rebounds. This response was
accompanied by an initial decrease in the CD4+ T lymphocyte
counts, which conditioned an inversion in the CD4 + /CD8+
lymphocyte ratio. After the second interruption period, the
CD4+ Tcell counts demonstrated a tendency to increase, and
even to exceed CD8+ T cell counts (Table 2 and Figure 2).
According to the absolute CD4+ Tcell counts, only one patient
had moderate immunosuppression (308—493 cells/ml) at the
end of the two first interruption periods and no child devel-
oped severe suppression during follow-up. On the other hand,
according to CD4+ percentages, six events of moderate
immunosuppression occurred, five of them during viral
rebounds, and although all children experienced some
decline in CD4+ percentages during follow-up, only one event
of severe immune suppression (CD4+ below 15%) occurred.
Thus, the nadir usually occurred during viral rebounds, and
was 18% for patient 1, 25% for patient 2, 14% and 16% for
patient 3, and 22% for patient 4 (Table 2).Table 2 Viral load and T lymphocytes of four HIV-1 infected child
HAART in cycles of 4 weeks off/12 weeks on therapy
Time of follow-up
Months Weeks
#
12 6 0 4 10
HAART STIa HAART
Patient 1
VL <400 <400 <400 616 000 <400
VL log10 <2.6 <2.6 <2.6 5.79 <2.6
CD4+ % 33.3 51 44 18 ND
Absolute CD4+ 829 927 858 648 ND
Absolute CD8+ 815 838 1029 2865 ND
Patient 2
VL <400 <400 <400 27 400 <400
VL log10 <2.6 <2.6 <2.6 4.44 <2.6
CD4+ % 41.9 39.9 34.7 34 ND
Absolute CD4+ 1199 1435 553 1445 ND
Absolute CD8+ 746 1032 511 2559 ND
Patient 3
VL <400 <400 <400 269 000 <400
VL log10 <2.6 <2.6 <2.6 5.43 <2.6
CD4+ % 30.4 33.8 40 14 ND
Absolute CD4+ 890 546 1215 308 ND
Absolute CD8+ 1121 670 1619 1846 ND
Patient 4
VL <400 <400 <400 159 000 <400
VL log10 <2.6 <2.6 <2.6 5.2 <2.6
CD4+ % 42.5 36.2 47 22 ND
Absolute CD4+ 1186 415 1168 887 ND
Absolute CD8+ 1159 511 1197 2896 ND
HAART, highly active antiretroviral therapy; STI, structured treatment
a STI measurements taken at the end of each 4-week period. ArrowsEvaluation of clinical response and treatment
adherence
There was no symptomatology related to both HIV infection
and adverse events related to HAART. At the end of the first
interruption cycle patient 1 presented an upper respiratory
tract infection with rhinorrhea, coughing, pharyngeal hyper-
emia, and cervical adenomegalies. These symptoms were
considered to have been caused by a viral infection, but the
etiology was not determined. Two more patients had acute
upper respiratory tract infections of undetermined etiology,
including the patient whose viral load rebounded at week 48
of follow-up coinciding with one of these events (patient 1).
There were no other symptoms during the follow-up. Chil-
dren gained weight and height during follow-up. The median
weight at the beginning of the first interruption period was
27.1 kg (range 19.2—37.2) and at week 48 of follow-up was
31.25 kg (range 24—40.1) ( p = 0.068). The median height at
the beginning of the first interruption period was 129 cm
(range 113—146) and at week 48 of follow-up was 132 cm
(range 121—154) ( p = 0.066). We did not detect any problems
related to treatment adherence.ren included in a structured treatment interruption program of
# #
16 20 26 32 36 42 48
STIa HAART STIa HAART
<400 17 800 <400 <400 25 100 <400 9530
<2.6 4.25 <2.6 <2.6 4.4 <2.6 3.98
32.2 22 ND 21 26 35 36
711 585 ND 673 485 534 692
963 1975 ND 2387 1280 958 1124
<400 19 800 <400 <400 5370 ND <400
<2.6 4.3 <2.6 <2.6 3.73 ND <2.6
25.2 ND 43 49 47 52 ND
685 ND 1567 1729 1388 2004 ND
635 ND 1818 1585 1434 1681 ND
<400 126 000 <400 ND 31 300 ND <400
<2.6 5.1 <2.6 ND 4.5 ND <2.6
34.3 16 38 ND 24 ND 35
763 493 766 ND 623 ND 489
871 2370 1166 ND 1775 ND 814
<400 125 000 <400 ND 140 000 ND <400
<2.6 5.1 <2.6 ND 5.15 ND <2.6
36.9 33 39 ND 27 ND 25
1115 895 796 ND 677 ND 572
1117 1689 1125 ND 1960 ND 1483
interruption; VL, viral load; ND, not determined.
indicate the beginning of each interruption period.
Figure 2 CD4+ percentage (filled triangles), and CD4+ (empty
squares) and CD8+ (empty circles) absolute T lymphocyte counts
of four HIV-1 infected children in a structured treatment inter-
ruption program (STI) in cycles of 4 weeks off/12 weeks on
HAART. Xn are the 4-week treatment interruption periods. Values
correspond to median.
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Although HAART has increased the survival of HIV-infected
patients, its high cost, the toxicity conditioned by its chronic
use, and failures in adherence that accumulate as time
passes are important limitations to its effectiveness in the
long term.1,5—7,22,23 STI of HAART can reduce the impact of
these three HAART limitations.8—17 It has been suggested
that STI of HAART may facilitate long term treatment, since
they can result in an increase in individual tolerance by
reducing the toxicity associated with the chronic use of
antiretrovirals, reducing the treatment burden, reducing
costs, improving adherence, and improving the quality of
life of the patient without risking the efficacy of the treat-
ment.7,9,10,12,17 Although in recent years abundant informa-
tion has been published on STI of HAART, most of this
information involves adult patients and remains controver-
sial.8—10,12,16,22—29 Thus, although the SMART study showed
that CD4+ guided episodic antiretroviral therapy in adult
patients increases the risk of opportunistic diseases and
death as a consequence of lowering CD4+ counts and increas-
ing viral load, a number of STI issues remain unresolved, such
as whether STI may be appropriate in circumstances other
than those used in the SMARTstudy.23,24 In the present study,
the viral, immunological and clinical impact of a HAART STI
program was evaluated in three cycles of 4 weeks off and 12
weeks on therapy in a cohort of four children with HIV
infection under chronic virological control.
The duration of the off/on HAART cycles in the present
study was chosen due to the fact that the prospective studies
carried out in adults have used STI periods as long as 3months
or as short as 2 weeks.6,9—11 In addition, a non-structured
HAART interruption study for intercurrent problems in
patients with controlled chronic infection and undetectable
viral load showed that interruptions of no longer than 4weeks
appear to be safe,7 and a recent prospective study evaluating
pediatric patients also demonstrated that interruption per-
iods of 4 weeks appear to be safe.17Progressively smaller viral rebounds at the end of the two
following interruption periods could suggest that temporary
exposure to HIV induces the development of a specific immune
response,7,9,10 and that if this tendency continues during a
longer follow-up, it could eventually delay the rebound occur-
rence and, therefore, patients could go without treatment for
longer periods of time. Results of some studies in adults
submitted to STI in the acute phase of HIV disease have
reported an increase in the viral control of the infection
due to a quantitative increase in the specific immune response
determined by T cells, which has suggested the possibility of
auto-immunization.However, results havenot been consistent
from one study to another.8—10,12,14,15 A prospective pediatric
study that included eight children submitted to progressively
longer antiretroviral treatment interruptions demonstrated
significant increases in HIV-specific immune responses and
reductions in viral RNA levels in children subjected to more
than 10 STI cycles.17 In contrast, in the PENTA 11 trial that
included 109 children with chronic HIV infection from nine
countries, 56 were randomized to undergo one or two CD4+
guided STI over 48 weeks. Although reductions in CD4+ counts
were greater in STI children, just four of themhad a CD4+ end-
point (<15% and for those 7 year-old <200 cells/mm3) vs.
one in continuous therapy. However, after 72 follow-upweeks,
94% in continuous therapy vs. 81% in STI were suppressed at
<400 copies of RNA/ml.30
In the present study, all the viral rebounds were followed
by a decrease in the VL to undetectable levels during the
treatment periods in the four patients, with only one excep-
tion. This finding suggests that the transitory viral rebounds
do not induce the selection of quasi-species resistant to
antiretrovirals. This risk is higher when there is viral replica-
tion in the presence of sub-therapeutic levels of such drugs,
as occurs when there is failure in the adherence to treat-
ment.1,8,9,13 Although we did not search for mutations
related to antiretroviral resistance, the results obtained
suggest that the risk of developing resistance and of second-
ary loss of viral control is low since, except for the first hours
of the interruption periods, there was no viral replication in
the presence of the circulating drug.9,10,13 Studies of struc-
tured and non-structured interruptions of HAART in adult
patients have reported mutations related to antiretroviral
resistance ranging between 0.75% and 45%.9,10,24 The VL of
the children in the present study would not have fallen to
undetectable levels in such a consistent manner if selection
of quasi-species with these types of mutations had occurred.
However, in this study it is possible that resistance had
occurred, particularly the mutation M184V conferring resis-
tance to 3TC, and as has been suggested by others it is
also possible that M184V could have resulted in a less fit
virus, which might explain the progressively lower viral
rebounds.31,32 The only exception with regard to the absence
of detectable VL during periods on HAARTwas a female child
in the final measurement. During sample collection for this
determination, the child presented upper respiratory tract
infection symptoms. Although no studies were done to deter-
mine the etiology of these symptoms, it was very probable
that they had a viral etiology. Although this patient’s VL
became undetectable at the next measurement, it has been
shown that such events induce transitory increases in viral
replication which recede once the intercurrent infectious
process resolves.33,34
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rebounds we found could be attributed to assay and biolo-
gical variations in HIV RNA levels. Although most of this
variability results from biologic variation and can be as much
as 3-fold (0.5 log10) for adult patients, changes greater than
0.5 log10 (3-fold) should be considered to reflect a biologi-
cally and clinically significant change in children older than 2
years.1,33—36 The median of the reductions in the rebound
magnitudes was higher than the 0.5 log10 attributed to this
biological variation, above all the magnitude of the third
rebound with respect to the first (0.8 log10). These reductions
also allowed the viral load at the end of the third rebound to
be established at least at the logarithm immediately below
that of the first rebound, and to always return to undetect-
able levels once treatment was reinitiated. Thus, it is very
unlikely that the reduction in the magnitude of the rebounds
observed was due exclusively to biological variability of HIV
RNA levels.35,36
Significant increases in CD8+ T lymphocyte counts
observed in most treatment interruption periods, which
coincided with the viral rebounds, suggest the development
of a vigorous T cytotoxic response secondary to the viral
stimulus, as has been demonstrated in some previous stu-
dies.8,9,17,27 However, this finding has not been consistent in
the different studies.8—10,12,14—16 In the present study, this
vigorous CD8+ T response was accompanied by an initial
decline in the CD4+ T lymphocyte counts and percentages.
In spite of this, the progressive increases in the CD4+ T
lymphocytes after the second interruption period, even
exceeding the CD8+ T lymphocyte counts, suggest that the
risk of loss of control of the immune response with the final
development of secondary clinical events is low. On the other
hand, the progressively smaller virological rebounds seem to
support one of the possible benefits of the HAART STI, an
increase in the specific immune response. By suspending
HAART, limited and temporary replication of the autologous
virus would allow induction of a specific immune response
against the HIV. If HAART interruption/reinitiation cycles are
applied in a continuous manner, a delay in the VL rebound
could be produced, which could increase with each inter-
ruption.9,10,12,17 Nevertheless, the decreases in CD4+ per-
centages observed in the short term follow-up in the present
study may raise concerns about the possibility of the devel-
opment of more immune problems if patients are submitted
to more cycling in a longer follow-up. Borkowsky et al.
demonstrated the development of an HIV-specific immune
response with progressive reductions of viral load in children
who were submitted to more than 10 progressively longer
antiretroviral treatment interruptions.17 Although immune
responses were not further characterized in the present
study, rendering us unable to determine whether the changes
observed are HIV-specific responses suppressing viral replica-
tion or whether they just represent non-specific immune
activation, our results could suggest that the development
of an HIV-specific immune response restricting viral replica-
tion is possible earlier and using a more simple schedule than
that used by Borkowsky et al. In addition, because only one
event of severe immunosuppression occurred, which was
transitory, early on during the follow-up and with no symp-
toms, the results obtained seem to suggest that the STI of
HAART applied to children in the conditions tested in this
study are immunologically safe.With the exception of one patient, no symptoms related to
the HIV infection occurred in the children. Although studies in
adults submitted to HAART STI have shown contrasting
results,10,15,27,28,37 the results of the present study suggest
that the risk of developing acute and opportunistic clinical
events is low with this HAART STI program for children with a
controlled chronic infection.
Although the number of patients in this study was small,
the consistency of the results obtained suggests that a HAART
STI program such as that evaluated in this study in children
with chronically undetectable VL causes progressively lower
virological rebounds. These results also suggest that such
rebounds are followed by a drop of VL to undetectable levels
and by the development of a vigorous CD8+ Tresponse with an
initial decline in the T helper response, which is followed by
progressive increases in the same. All this suggests that
temporary and repeated exposure to the autologous HIV
may induce the development of a specific immune response.
In addition, because no serious clinical events related to HIV
occurred and despite the immune events we detected, these
results also seem to suggest that this STI program could be
safe from the clinical and immunological point of view.
However, evaluation of larger cohorts over longer periods
of time, including different antiretroviral regimens, and,
above all, controlled clinical trials, are needed before defi-
nitive conclusions about the benefits and safety of STI of
HAART in children may be drawn.
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